Pharma outsourcer Almac has signed a deal that allows it to add emergency services to its clinical trial management platform, allowing sponsors to quickly handle unforeseen problems and minimize the need for unblinding data, the company said.
Fast-growing German CRO Accovion has made its way into France, opening up a new subsidiary as it works to become Europe's biggest independent pharma outsourcer.
Swedish contract drug developer Recipharm has signed a deal to extend its reach into France, buying a new facility and partnering with a local firm.
The Department of Health and Human Services and the National Institutes of Health are proposing new rules that would greatly expand the number of clinical trials required to publicize their results, a move that could change how CROs handle data.
Medidata and partner TransCelerate BioPharma, a nonprofit run by the world's largest drugmakers, are amplifying their call for clinical trial runners to embrace new technology, unveiling study results that support the adoption of risk-based monitoring.
PRA Health Sciences and INC Research have both seen their shares tick upward since pulling off IPOs earlier this month, a sign that, despite biotech's boom and bust, the window for CRO debuts remains open.
NextDocs, a venture-backed document-management company, has signed a deal with Parexel to integrate its services with the CRO's growing eClinical platform.
After a weather-related shutdown at a New Mexico facility helped tank its quarterly earnings, AMRI has rectified the issue, bringing its plant back online as it works to get back on the path to growth.
Ohio-headquartered CRO Ricerca Biosciences can put off its liquidation plans, as the company has found an acquirer to keep its doors open just ahead of a self-imposed deadline.
The U.K.'s Consort Medical has closed its $374 million buyout of contract drug developer Aesica, part of an effort to diversify its offerings and expand the market for its proprietary drug delivery devices.
Pharma outsourcer Recipharm has acquired a Portuguese contract drug developer for €112.3 million ($140 million) in cash and stock, bolstering its global scale and further consolidating the world of R&D service providers.
Parexel International has cut the ribbon on a new clinical trial supply hub in Europe, centralizing the CRO's continental logistics services as part of a companywide effort to more efficiently conduct studies around the globe.
Catalent has acquired another R&D tech firm, snapping up Micron Technologies and its particle sizing capabilities as the recently IPO'd company works to expand its share of the drug development market.
Chinese CRO WuXi PharmaTech is forecasting a better-than-expected 2014 after a strong third quarter and some timely deals, moving into the new year with hopes for continued global growth.
Charles River Laboratories has extended its partnership with CHDI Foundation, signing up for 5 more years of work spotlighting new treatments for Huntington's disease.
Indian CRO GVK Biosciences is expanding its capacity in early-phase R&D, buying a local preclinical testing outfit as it works to expand its reach.
Many clinical trials rely on patient-reported outcomes to determine whether drugs are working, but with disparate methods employed across the industry, it can be difficult to compare the results from one study with those of another. With that in mind, the FDA has recruited CRO giant Icon to help develop an industry standard for patient polling in antibacterial R&D.
PPD has expanded its relationship with eClinical outfit Medidata, combining technologies in risk-based monitoring to help sponsors use real-time safety data to make decisions on clinical trials.
Contract drug developer AMRI watched its shares plummet after underperforming in the third quarter, an earnings miss the company blamed on declining demand, spiking costs and bad weather in the desert.
Chinese CRO WuXi PharmaTech has opened up shop in Israel, cutting the ribbon on a Tel Aviv outpost and aligning itself with a local investor to expand its presence in the country.